GEISTWERT Rechtsanwälte Lawyers Avvocati

ORD_598583/2023

Sanofi Biotechnologies SAS, Regeneron Pharmaceuticals Inc. v. Amgen Inc. , Amgen GmbH, Amgen Europe B.V., Amgen NV, Amgen S.R.L., Amgen B.V., Amgen S.A.S.

Date
2025-05-13
Division
Düsseldorf (DE) Local Division
Type of action
Infringement Action
Language
EN

Metadata

Case IDORD_598583-2023-d5cfde99ea74
Case number
Registry numberORD_598583/2023
Order referenceORD_598583/2023
Keywords
Headnotes

Documents and full text

Extractor: pypdf | Pages: 42

1 Düsseldorf Local Division UPC_CFI_505/2024 Decision of the Court of First Instance of the Unified Patent Court delivered on 13 May 2025 concerning EP 3 536 712 B1 Headnotes: 1. In the case of a second medical use claim, a substance or composition within the mean- ing of Art. 54(4) EPC is used for any specific use which is not comprised in the state of the art. Such a therapeutic use can be a new indication, e.g. a disease not yet t reated by the claimed substance, or an indication for a new group of patients. 2. For a finding of infringement of a second medical use claim, the alleged infringer must offer or place the medical product on the market in such way that it leads or may lead to the claimed therapeutic use of which the alleged infringer knows or reasonably should have known that  ...